CDK4 and neoplasm: In conclusion, this proof‐of‐concept study is the first to demonstrate that longitudinal assessment of tumor fractions using untargeted mFAST‐SeqS as a surrogate may harbor important prognostic information on disease progression in HR+/HER2− breast cancer patients undergoing CDK4/6 treatment.